Archives for category: LYME DISEASE

Northern Ireland;s healthcare just approved the ActiPatch for reimbursement

Scotland also.  

Thanks to srinsocal, one of the names I always click on. This shows Andrew Whelans “Letter From the President” (excerpted below) is quickly coming to fruition.

This type of good news is becoming more commonplace in Bioelectronics land. Time was when news a tenth of this magnitude would have had shareholders euphoric for a month. What I like is this will give the stock some momentum on Monday, hopefully help us break out into the 0.02 area.  I think you will find as this stock rises these slow painful ticks will escalate as the prices rises, rewarding all who bought in December 2017, especially.

(Excerpt from President’s Letter)

Letter from the President

Marketing Expansion

We believe that expanded market clearance from the FDA will enhance the market value and attractiveness of the ActiPatch product line.

Our economic and clinical studies for the National Health Services allowed us to gain a drug tariff listing for reimbursement in England and Wales allowing the following:

  • Prescription coverage for the majority of the 56 million populations of England and Wales.
  • A drug tariff listing for reimbursement is expected to accelerate reimbursement clearance request in other nations.
  • Has the potential to open the US market to the 90 million people with prescription payment coverage in Health Maintenance Organizations (HMO’s), Accountable Care Organization, and other third party payers to provide and pay the cost of ActiPatch therap

I don’t really have the heart to read about Syria.   America has real problems, intrinsic problems, and these internal problems are forcing us to take actions which are basically indefensible.

If one thing has been proven, time and time again since 9-11, it is this–people are liars. American politicians are mainly liars, the press is mainly liars, international spy agencies seem to lie on demand. Foreign governments are all liars.

So what is truth? Well, truth is forensics at a crime scene. Facts are true. America has 20 trillion in debt, and this is climbing. Fact. There are forces who control America through this debt. For instance, if some other nation owned enough American T-Bills, they could pull the plug on the American economy just by dumping the T-Bills on the open market. This is factually accurate as a statement.

I cannot speak for other countries, but as a group, Americans are blissfully ignorant of economic history. Many have heard of Napoleon versus Wellington at Waterloo as a military encounter, and there are usually some trite statements about the whys and wherefores of it, but the economic history of this engagement is so fascinating and pivotal that it really is a shame it will never be taught in schools in current America.

Let’s break it down to two stock exchanges, the one in England and the one in France (London and Paris). Both sides hate each other, yada yada, and are at war.

There is an up and coming banking family, the Rothschilds, who by intelligence, hard work and loyalty to family, had carved a niche in several major cities. These guys were smart. They had developed better communication  between themselves, brothers who ran banks in various European trade centers, and because they loaned money to both sides in this war between England and France, their couriers were allowed to travel unmolested through militarized zones.

Also, since I am from a little ethnic coal mining town, I would wager that with their banking empire came a lot of street smarts and connections. Sometimes, people need to be forced to pay up. I personally grew up knowing of people who got dropped in rivers for welshing on gambling and cocaine debts. Lending money is a rough business, you simply do not succeed at it unless you are willing to get your hands dirty.  True, there are legitimate banks who do not resort to violence. They just get the sheriffs to forcibly evict you and your family and drop all your stuff off in a dumpster. No violence there.

Anyway, back to the Battle of Waterloo. The Rothschild’s backed both sides. When the top London guy heard the English had won, he created a panic by dumping everything English at fire-sale prices. People flipped, thinking he had insider info (he did), and they started selling. At the end of the day, Rothschild bought, bought up all of England basically, at rock bottom prices.

Meanwhile, in Paris, the opposite trick was played. The top Rothschild in Paris started buying like a madman. All the French figured he knew the French had won so they started buying as well. At the top, the Paris Rothschild started selling. When the bad news of Napoleon’s defeat hit, French markets collapsed, and Rothschild had the capitol to buy up France a a bargain as well.

Now, someone might say this is capitalism at its finest. I withhold judgement except to say I never heard of this admirable stroke of genius in any history class, and never knew a history major who I thought might have known it. As for this being fair play, let us consider this salient fact–shortly before the Battle of Waterloo, the French Rothschild pulled Napoleon’s credit. Bonaparte could not get gold to finance his military campaign.

Napoleon famously said “an army marches on its stomach”, but no one ever asked what prompted this declaration. Pulling his credit led to a predictive outcome.

Now, England and France are joining the USA in bombing Syria. I know something about the street myself, enough to know hired goons when I see them.

This cartoon might help you begin your journey to some understanding of economic history–The American Dream.




I usually mention Bioelectronics. I sincerely think this slow rise is being done by pros. I think this is going to become a real stock, on a real exchange. The pipeline is ridiculous. The immediate drivers of this stock are not the migraine and menstrual pain applications, yet these are the real bonanzas of this treatment. The volatility of the markets will help this stock, as big money looks for a safe haven that has a lot of return.

If things continue apace, the short position in this stock will be forced to cover, and this will cause a blow off top. I will sell some at this point and then buy back in when the short squeeze dissipates, ideally, happy to pick the pockets of these snitches. I have not yet seen a blow-off top, it might happen several times as the pipeline of positive news hits.


This Dewmboom post is too good not to share. We are starting to get the right marketers for this thing.

Check out the BIEL Chart below as well.





This update letter was posted on Bioelectronic Corporation’s website yesterday by Andrew Whelan.

It’s good to go on record with this, because they are getting to the point where intellectual property theft will become a real issue.

I would prefer an American company buy them, but the most likely buyer based on this is BRAUN. They are actually the best fit, and have played this extremely well. Someone is accumulating this stock right now, it might well be a BRAUN or a proxy for them.

(update 4-7-18: additional thoughts on this letter–2 formal FDA pre-subs being submitted soon. One for Back Pain, which will be the third clearance for muscle pain and will also result in General Clearance for Muscular Pain, the world’s first FDA approved electroceutical aspirin.

The second one is for post surgery, including Cesarean section swelling. This was my first exposure to this therapy, when post-birth at Mt. Sinai Hospital in Manhattan they wheeled this large microwave looking appliance and put some electrode looking things on my wife’s stomach. This was 11 years ago, but the therapy has been around for 50 years. The key thing here is the ActiPatch is portable and inexpensive. You don’t need an instrument which costs a couple hundred grand and you can’t wear around with you while you conduct your life. This particular hospital is world famous. Famous people rent out entire floors when they have babies. It is considered one of the most technologically advanced hospitals in the world, and Bioelectronics has them beat. Do you see where I am going with this?


Letter from the President

The following is a letter from the President of BioElectronics Corporation (OTC Pink: BIEL) to Shareholders:

April 4, 2018

Dear Fellow Shareholders,

This letter is to report on our recent progress in marketing and product development. We have established the following:

  • Domestic and international market presence with products that have proven marketability and customer acceptance.
  • Unique, patented technology platform of wearable, safe, and cost effective pulsed shortwave neuromodulation devices for neurological disorders, which include:
    • Chronic Musculoskeletal Pain
    • Menstrual Pain
    • Heel and Foot Pain
    • Migraine Headaches
    • Postoperative Recovery and Pain
    • Interstitial Cystitis (Overactive Bladder and Pelvic Pain)

We are continuing to solicit new international and domestic sales and marketing partners for distribution and licensing, while strengthening our relationship with existing partners. To aid in this effort we have engaged an accomplished sales and marketing pharmaceutical consultant to assist in introduction and negotiations of sales and marketing partnerships.

US Market Clearance

ActiPatch®, Musculoskeletal Pain Therapy

We are in the process of expanding the US market clearance from relief of osteoarthritis of the knee pain and plantar fasciitis. Our goal is to obtain general clearance for musculoskeletal pain. To achieve this, we have submitted a chronic back pain clinical study to the US FDA as a formal Pre-Sub. The initial meeting with the FDA is tentatively scheduled for May 9th.  Prior guidance from the FDA indicated that a third clinical study was required before expanding the current market indications to cover all musculoskeletal pain. We are hopeful that the process will be completed rapidly, however we will not have a good estimate of this market clearance date until the completion of the May 9th meeting.

Postoperative Recovery and Pain

We have submitted a formal Pre-Sub to the US FDA for guidance in obtaining market clearance for the palliative treatment of postoperative pain and edema. The application is supported by postoperative clinical studies on breast augmentation and caesarean section.

Marketing Expansion

We believe that expanded market clearance from the FDA will enhance the market value and attractiveness of the ActiPatch product line.

Our economic and clinical studies for the National Health Services allowed us to gain a drug tariff listing for reimbursement in England and Wales allowing the following:

  • Prescription coverage for the majority of the 56 million populations of England and Wales.
  • A drug tariff listing for reimbursement is expected to accelerate reimbursement clearance request in other nations.
  • Has the potential to open the US market to the 90 million people with prescription payment coverage in Health Maintenance Organizations (HMO’s), Accountable Care Organization, and other third party payers to provide and pay the cost of ActiPatch therapy.

The ActiPatch registry studies report that people buy the device because it is effective, drug-free, has no harmful side effects and overall improves quality of life. We are continually working to solve existing minor issues with the use of ActiPatch. To improve the product, we are introducing custom-design kinesiology tape strips to attach the device to the body. Aside from improving user comfort, this allows us to promote a single multi-purpose box with the added benefit of reducing retail shelf space. We believe this will then allow us to sell the 7-day trial devices from pharmacy shelves.

B. Braun UK

This is an important development for BioElectronics. B Braun has been using RecoveryRx to improve recovery following joint replacement for many years, although in limited surgeries. However, new advances in day surgery for joint replacement have expanded our opportunity. B. Braun has recently completed a pilot program in the UK evaluating day for joint replacement. The United Kingdom’s Group day surgery program for knee and hip replacement patients and is now being implemented on a national basis. Currently there are 80,000 procedures per year involving B Braun. The “fast-track” same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a special wireless technology tablet. Upon hospital discharge, each patient will be given an ActiPatch medical device and a prescription for 6 additional devices to help accelerate recovery and mitigate the postoperative pain.  A similar program is in development for spinal surgeries.

On an international level, B. Braun’s 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services.  It is anticipated that B. Braun’s German Group will roll out the same day hip and knee replacement program in the next few months.

Smart Insole – Heel Pain Relief

We have redesigned the Smart™ Insole plantar fasciitis insole to enhance user comfort. We are awaiting a written License and Supply Agreement for the product.

Clinical Research to Expand Market Clearance and Acceptance

Allay®, Menstrual Pain Therapy

28% of women are in the menstrual phase of life and 60% have moderate to severe menstrual pain, or 17% of women.

Previously our medical devices were classified as high risk class III by the US FDA. While our existing pilot clinical study for menstrual pain reported exceptional results for menstrual pain, to publish a clinical study and obtain US market clearance, we are collaborating with the University Hospital at Birmingham, UK. The researchers here are world renowned thought leaders in women’s health and are conducting a double-blind randomized controlled trial to evaluate the efficacy of ActiPatch in reducing menstrual pain ( listing NCT03394547).

You can view the existing clinical evidence and our commercials at

Prevention of Episodic Migraines Headaches

Migraines affect 36 million men, women and children in the United States alone. The facts are:

  • In addition to attack-related disability, migraine interferes with a sufferer’s ability to function in everyday life, whether that is going to school or work, caring for family or enjoying social activities.
  • About 14m people experience chronic daily headache – attacks occur at least 15 days per month.
  • For more than 90% of all sufferers, migraine interferes with their education, career and social activities.
  • Depression, anxiety, and sleep disturbances are common for those with chronic migraine.
  • People with migraine use about twice the medical resources –including prescription medications and office and emergency room visits– as non-sufferers.

Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception; since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attack. There is pilot data that ActiPatch can help mitigate this sensitization, so a study has been completed to determine the efficacy of ActiPatch in preventing chronic, episodic migraines. The data from the study will be analysed in the next few weeks. We believe this data will allow us to work towards developing a product as a migraine therapy and allowing us to obtain market clearance.

Postoperative Recovery and Pain

Working with our distributor in Lebanon we are conducting a double blind placebo randomized controlled trial on total knee replacement ( NCT03395444). Through our long standing association with B. Braun UK, RecoveryRx has been determined to be a valuable aid in joint replacement surgery. This clinical study will allow us to gain worldwide recognition and allow for expanded marketing and acceptance of the RecoveryRx as a standard of post-operative care following joint replacement.

Interstitial Cystitis (Overactive Bladder and Pelvic Pain)

This study is a University of Texas, McGovern Medical School sponsored double blind randomized controlled trial.  The goal is to determine how well the ActiPatch therapy works in treating patients with interstitial cystitis, bladder pain syndrome and overactive bladder. Interstitial cystitis and bladder pain syndrome are chronic bladder health conditions that greatly affect quality of life.  These conditions create intermittent feelings of pain and pressure in the bladder area. The study is expected to recruit 60 women who are urology patients of the University’s hospital.

At least 35 million Americans have overactive bladder. Lower urinary tract symptoms, urgency, and pelvic pain are common complaints to urologists and primary care physicians.

Additional Bioelectronic Product Opportunities 

As we develop the organizational structure we envision additional opportunities in chronic wounds, neuropathy, hypertensive therapy, etc.  Most importantly future growth is not dependent on large capital outlays for research and development.

Immediate Sales Growth

We anticipate imminent solid sales growth from the following programs:

  1. NHS reimbursement of ActiPatch in the United Kingdom
  2. Braun, UK same day surgery program
  3. US professional sales to physical therapist, nursing homes, managed care providers
  4. International geographic market expansion; and,
  5. Domestic and International License and Supply Agreements for ActiPatch and the Smart Insole products.

Thank you for your support.


Andrew Whelan, President

* * * * *


Paul Knopick

Posting this for the BIEL sharholders who read this blog.

Let me recap–this might get removed so I will also put a link here.

Asian ads are different–a life insurance ad will be 20 minutes long and tell an entire story.  They are like movie shorts.


Anyway, watch this all the way through, and if as a BIEL shareholder you do not stand up and cheer at the end (metaphorically), then apologies, but perhaps you are not as true blue. This ad rocks. Showing how its done, in any language, kudos, kudos, kudos.

To me its pretty simple–if BIEL can’t market and sell its product, they need to sell the company. The shareholders deserve some respect, and the public deserves the opportunity to use this technology.

If the new company can’t or won’t market this either, the situation would essentially be the same as it is now, but at least the attempt would have been made, and the shareholders would have gotten paid.

It’s been almost a year since BIEL got two FDA approvals and I still can’t go to a store and buy a Sportspatch. This is an epic fail.

Free Book! click here.

Lyme and Punishment: Lost in the Labyrinth of Misdiagnosed Lyme Disease: a personal experience, free now!